Introduction
One of the major limitations to successful antimicrobial therapy of enteric bacterial pathogens has been the progressive emergence of resistance to these drugs, particularly in the developing countries. [1] With a marked increase in antibiotic resistance among enteric bacterial pathogens, it has become imperative to find alternative effective antimicrobial agents. Among the oral antimicrobial agents, the fluoroquinolones and the broad-spectrum cephalosporins are the only groups whose efficacy against enteric pathogens of the family Enterobacteriaceae has not yet been compromised by acquired resistance. However, the fluoroquinolones are not yet recommended for use in paediatric patients because of articular damage caused by these drugs and the broad-spectrum cephalosporins because they are quite expensive and likely to induce TEM-like β lactamases, which can hydrolyze the broad-spectrum cephalosporins. [2] Erythromycin is an old antibiotic that has been used to prevent infections caused by gram -ve enteric pathogens. [3] Use of erythromycin is limited by frequent G.I side effects was carried out by the Kirby-Bauer disk diffusion method. The MIC for azithromycin was determined by agar dilution and E-test methods. The vial containing azithromycin powder was obtained from Alembic Pharma Ltd, India. and dissolved in distilled water as stock solution according to the manufacturer's instruction, which was used for the agar dilution method. The E-test strip for azithromycin was obtained from Hi-Media, India. The control organism Escherichia coli ATCC 25922 was included with each set of isolates tested, which was obtained from Dr. (Mrs.) Savitri Sharma (Editor IJMM), L.V. Prasad Eye Institute, Bhubaneshwar.
Results
One hundred fifty-nine bacterial strains belonging to the family Enterobacteriaceae were isolated from the clinical samples. Of the 159 isolates of the family Enterobacteriaceae, 96 (60.37%) were E. coli followed by Klebsiella species 45 (28.31%). Salmonella and Shigella species were 6 each (3.77%) whereas Enterobacter and Citrobacter species were 3 each (1.88%). Maximum isolates were obtained from urine 117 (73.58%), followed by sputum and stool (7.54%) each.
On routine antimicrobial susceptibility testing by the disk diffusion method, E. coli and Klebsiella species were found to be most sensitive for amikacin (78.1% and 73.3%), followed by gatifloxacin (50% and 57.7%), respectively. Salmonella and Shigella species were found to be most sensitive to azithromycin (83.3%), followed by amikacin (50%). Enterobacter species showed an equal sensitivity to both amikacin and gatifloxacin (66.6%) whereas Citrobacter species showed an equal sensitivity to amikacin, ceftriaxone and cefotaxime. In comparison with other isolates, E. coli showed maximum resistance to azithromycin (85.4%) [ Table 1 ].
On determination of the MIC of azithromycin by the agar dilution method among 96 strains of E. coli, 13(13.54%) strains showed an MIC <8 µg/mL whereas 42 (43.75%) strains had an MIC ≥256 µg/mL. Similarly, when tested for Klebsiella species, 21 (46.6%) strains showed an MIC <8 µg/ mL whereas 3 (6.66%) strains had an MIC ≥256 µg/mL.
The Salmonella and Shigella species showed an 83.3% and 66.6% sensitivity, respectively, but the Enterobacter and Citrobacter species were showed a 100% resistance (i.e., MIC > 8 µg/mL).
When the MIC of azithromycin was determined by the E-test method, 18 (18.7%) strains of E. coli were found to be in the susceptible range (i.e., <8 µg/mL) and 22 (22.9%) strains had an MIC >128 µg/mL. Among the 45 strains of Klebsiella species isolated, 29 (64.44%) strains had an MIC in the susceptible range. The Salmonella and Shigella species showed a 100% sensitivity to azithromycin. The Enterobacter and Citrobacter species showed a 66.6% and 33.3% sensitivity to azithromycin, respectively.
A comparison of the MIC of azithromycin by agar dilution, E-test and disk diffusion methods was made. It was found that 18.75% strains of E. coli were susceptible by E-test in comparison with 14.58% and 13.54% by disk diffusion and agar dilution, respectively. For the Klebsiella species, 64.44% strains showed an MIC in the susceptible range by E-test in comparison with 48.8% and 46.6% by disk diffusion and agar dilution, respectively. The Salmonella and Shigella species showed a 100% sensitivity to azithromycin the by E-test but an 83.33% sensitivity by the disk diffusion method. The MIC of Salmonella to azithromycin by agar dilution method was same as that of disk diffusion, but for Shigella species it was 66.66%. Enterobacter and Citrobacter species showed a 100% resistance to azithromycin by the agar dilution method but a 33.33% susceptibility by the disk diffusion method. Although Enterobacter showed a 66.66% susceptibility by the E-test, the Citrobacter species showed only a 33.33% susceptibility by the E-test method [ Table 2 ].
The percentage of agreement between the different test methods show a 96.8% agreement between disk diffusion and agar dilution, an 88% agreement between agar dilution and E-test and a 91.2% agreement between disk diffusion and E-test methods [ Table 3 ].
Discussion
Azithromycin penetrates into cells effectively and this intracellular penetration explains the therapeutic efficacy of this drug against the predominantly intracellular pathogens like S. typhi. The ability of azithromycin to achieve intracellular concentration in monocytes is 231 times and in polymorphonuclear leucocytes is 83 times greater than that of serum concentration. [8, 9] It has a long half life of 2-3 days.
The intracellular concentration appears to be essential for its therapeutic activity in typhoid fever. The availability of a paediatric suspension of azithromycin provides an opportunity to examine the efficacy and safety of this drug in young children with typhoid fever. The in vitro resistance of azithromycin to different clinical isolates was reported to be 12% by Butler et al. [10] In the present study, the antibiotic susceptibility pattern of 159 clinical isolates belonging to the family Enterobacteriaceae was studied. Among the 159 clinical isolates, 96 were E. coli (60.37%), followed by Klebsiella spps. 45 (28.31%). The majority of these isolates were obtained from urine samples. On studying the antibiotic susceptibility patterns of these clinical isolates by the disk diffusion method, it was found that amikacin was the most sensitive drug for all the isolates of the family Enterobacteriaceae, except Salmonella and Shigella species, where azithromycin was found to be more sensitive. Although previous studies showed an excellent in vitro activity of azithromycin against the most common enteric bacterial pathogens, [11] in our study, an increasing resistance of azithromycin to all the enteric bacterial pathogens except Salmonella and Shigella species was obtained. Thus, it was found to be the most effective antimicrobial agent for these two species.
On comparison of the MIC by the different test methods, it was found that MICs obtained using the E-test was lower than those by agar dilution regardless of the species of organism tested. The correlation between the E-test and the agar dilution MICs varied greatly depending on the antimicrobial agent tested. [12] If the performance of these test methods is ranked by the percentage agreement of the interpretive results with the consensus interpretive results (highest agreement ranked best), the rank order would be E-test>disk diffusion>agar dilution. [13] Our study also showed a similar type of result. In our study, the percentage of agreement between agar dilution and E-test is 88%, between disk diffusion and agar dilution is 96.8% and between disk diffusion and E-test is 91.2%.
Emergence of antimicrobial drug resistance in S. typhi is a global problem [14, 15] and was the compelling reason to undertake the trial of a new alternative antibiotic for typhoid fever. This study showed an excellent in vitro activity of azithromycin against Salmonella and Shigella species. Because of its good intracellular activity and relatively low MICs for enteropathogens, this drug may become an important addition to our antimicrobial strategies for the treatment of typhoid fever and also for bacillary dysentery. Further studies to define its role in the management of enteric bacterial infections may be required. 
